InvestorsHub Logo
Followers 49
Posts 4029
Boards Moderated 0
Alias Born 07/10/2005

Re: None

Thursday, 01/28/2021 9:36:31 AM

Thursday, January 28, 2021 9:36:31 AM

Post# of 1990
MIAMI --(BUSINESS WIRE)-- Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR ), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Zofin™, in the treatment of patients diagnosed with chronic obstructive pulmonary disease (COPD).

***Disclaimer & Disclosure***: I make no guarantee as to the accuracy or validity of information in this message. Messages posted reflect my own opinions and/or those of others, and are posted for entertainment purposes only.